{"title":"基于c反应蛋白基因多态性分析的粘膜下浸润性胃癌淋巴结转移风险","authors":"Kotaro Honda, Kohei Taniguchi, Kazumasa Komura, Tomohito Tanaka, Hidero Yoshimoto, Kentaro Matsuo, Yoshiro Imai, Ryo Tanaka, Mitsuaki Ishida, Yoshinobu Hirose, Satoru Motoyama, Sang-Woong Lee","doi":"10.1007/s10147-025-02884-1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The 1846C > T polymorphism of the C-reactive protein (CRP) gene is associated with an increased risk of lymph node metastasis in various cancers. This study aimed to examine its association with lymph node metastasis in gastric cancer.</p><p><strong>Methods: </strong>A retrospective analysis of the 1846C > T CRP polymorphism was conducted in patients with submucosal (SM) gastric cancer from April 2011 to March 2022. Genotyping was performed using polymerase chain reaction fragment length polymorphisms. Patients were categorized into differentiated and undifferentiated groups and then subdivided into C/C + C/T and T/T genotypes. We assessed correlations between polymorphisms, lymph node metastasis, and lymphatic and venous invasion. Two sub-analyses were conducted in the differentiated gastric cancer group.</p><p><strong>Results: </strong>Among 111 patients with SM gastric cancer, 81 had differentiated tumors, whereas 30 had undifferentiated tumors. In the differentiated group, 4.5% of C/C and C/T genotypes and 18.9% of T/T genotypes exhibited lymph node metastasis, with a 95% negative predictive value. Excluding pT1b1 and tumors ≤ 3 cm, lymph node metastasis occurred in 5.3% of C/C and C/T genotypes and 20.6% of T/T genotypes, with a negative predictive value of 94.7%. For cT1bN0 cases, lymph node metastasis was 0% in C/C and C/T genotypes and 15.8% in T/T genotypes, with a negative predictive value of 100%.</p><p><strong>Conclusions: </strong>In this exploratory study, the 1846C > T CRP polymorphism suggests that patients with differentiated SM gastric cancer carrying the C/C or C/T genotype have reduced risk of lymph node metastasis, potentially minimizing the need for additional surgery after endoscopic submucosal dissection.</p>","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Lymph node metastasis risk in submucosal invasive gastric cancer based on C-reactive protein gene polymorphism analysis.\",\"authors\":\"Kotaro Honda, Kohei Taniguchi, Kazumasa Komura, Tomohito Tanaka, Hidero Yoshimoto, Kentaro Matsuo, Yoshiro Imai, Ryo Tanaka, Mitsuaki Ishida, Yoshinobu Hirose, Satoru Motoyama, Sang-Woong Lee\",\"doi\":\"10.1007/s10147-025-02884-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The 1846C > T polymorphism of the C-reactive protein (CRP) gene is associated with an increased risk of lymph node metastasis in various cancers. This study aimed to examine its association with lymph node metastasis in gastric cancer.</p><p><strong>Methods: </strong>A retrospective analysis of the 1846C > T CRP polymorphism was conducted in patients with submucosal (SM) gastric cancer from April 2011 to March 2022. Genotyping was performed using polymerase chain reaction fragment length polymorphisms. Patients were categorized into differentiated and undifferentiated groups and then subdivided into C/C + C/T and T/T genotypes. We assessed correlations between polymorphisms, lymph node metastasis, and lymphatic and venous invasion. Two sub-analyses were conducted in the differentiated gastric cancer group.</p><p><strong>Results: </strong>Among 111 patients with SM gastric cancer, 81 had differentiated tumors, whereas 30 had undifferentiated tumors. In the differentiated group, 4.5% of C/C and C/T genotypes and 18.9% of T/T genotypes exhibited lymph node metastasis, with a 95% negative predictive value. Excluding pT1b1 and tumors ≤ 3 cm, lymph node metastasis occurred in 5.3% of C/C and C/T genotypes and 20.6% of T/T genotypes, with a negative predictive value of 94.7%. For cT1bN0 cases, lymph node metastasis was 0% in C/C and C/T genotypes and 15.8% in T/T genotypes, with a negative predictive value of 100%.</p><p><strong>Conclusions: </strong>In this exploratory study, the 1846C > T CRP polymorphism suggests that patients with differentiated SM gastric cancer carrying the C/C or C/T genotype have reduced risk of lymph node metastasis, potentially minimizing the need for additional surgery after endoscopic submucosal dissection.</p>\",\"PeriodicalId\":13869,\"journal\":{\"name\":\"International Journal of Clinical Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2025-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Clinical Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10147-025-02884-1\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02884-1","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景：c反应蛋白（CRP）基因1846C bbbbt多态性与多种癌症中淋巴结转移风险增加有关。本研究旨在探讨其与胃癌淋巴结转移的关系。方法：回顾性分析2011年4月至2022年3月粘膜下（SM）胃癌患者1846C > T CRP多态性。采用聚合酶链反应片段长度多态性进行基因分型。将患者分为分化组和未分化组，再细分为C/C + C/T和T/T基因型。我们评估了多态性、淋巴结转移、淋巴和静脉侵袭之间的相关性。分化型胃癌组进行了两个亚组分析。结果：111例SM胃癌患者中，分化肿瘤81例，未分化肿瘤30例。在分化组中，4.5%的C/C和C/T基因型和18.9%的T/T基因型出现淋巴结转移，阴性预测值为95%。排除pT1b1和肿瘤≤3 cm， C/C和C/T基因型发生淋巴结转移的比例为5.3%，T/T基因型为20.6%，阴性预测值为94.7%。在cT1bN0病例中，C/C和C/T基因型淋巴结转移率为0%，T/T基因型为15.8%，阴性预测值为100%。结论：在这项探索性研究中，1846C > T CRP多态性提示携带C/C或C/T基因型的分化型SM胃癌患者淋巴结转移的风险降低，可能减少内镜下粘膜下剥离后额外手术的需要。
Lymph node metastasis risk in submucosal invasive gastric cancer based on C-reactive protein gene polymorphism analysis.
Background: The 1846C > T polymorphism of the C-reactive protein (CRP) gene is associated with an increased risk of lymph node metastasis in various cancers. This study aimed to examine its association with lymph node metastasis in gastric cancer.
Methods: A retrospective analysis of the 1846C > T CRP polymorphism was conducted in patients with submucosal (SM) gastric cancer from April 2011 to March 2022. Genotyping was performed using polymerase chain reaction fragment length polymorphisms. Patients were categorized into differentiated and undifferentiated groups and then subdivided into C/C + C/T and T/T genotypes. We assessed correlations between polymorphisms, lymph node metastasis, and lymphatic and venous invasion. Two sub-analyses were conducted in the differentiated gastric cancer group.
Results: Among 111 patients with SM gastric cancer, 81 had differentiated tumors, whereas 30 had undifferentiated tumors. In the differentiated group, 4.5% of C/C and C/T genotypes and 18.9% of T/T genotypes exhibited lymph node metastasis, with a 95% negative predictive value. Excluding pT1b1 and tumors ≤ 3 cm, lymph node metastasis occurred in 5.3% of C/C and C/T genotypes and 20.6% of T/T genotypes, with a negative predictive value of 94.7%. For cT1bN0 cases, lymph node metastasis was 0% in C/C and C/T genotypes and 15.8% in T/T genotypes, with a negative predictive value of 100%.
Conclusions: In this exploratory study, the 1846C > T CRP polymorphism suggests that patients with differentiated SM gastric cancer carrying the C/C or C/T genotype have reduced risk of lymph node metastasis, potentially minimizing the need for additional surgery after endoscopic submucosal dissection.
期刊介绍：
The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
